PROTEONIC UNVEILS EARLY ACCESS PROGRAM, ELEVATING VIRAL VECTOR TITERS WITH TRANSFORMATIVE LV-2G UNIC® TECHNOLOGY

    With the official launch onMarch 20, 2024, ProteoNic extends a warm invitation to CDMOs, biotechs, and biopharmaceutical companies to experience firsthand the transformative potential of LV-2G UNic ®. By seamlessly integrating this cutting-edge vector technology into existing systems, participants can achieve remarkable enhancements in titers, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency. Frank Pieper...

 

With the official launch on March 20, 2024, ProteoNic extends a warm invitation to CDMOs, biotechs, and biopharmaceutical companies to experience firsthand the transformative potential of LV-2G UNic^®. By seamlessly integrating this cutting-edge vector technology into existing systems, participants can achieve remarkable enhancements in titers, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency.

Frank Pieper, CEO of ProteoNic, shared his excitement about the program's potential impact, stating, "The LV-2G UNic^® Early Access Program will serve as a launching platform for our viral vector manufacturing innovation. By offering early access to our state-of-the-art vector technology, we empower researchers to unlock unprecedented levels of efficiency and productivity in viral vector manufacturing."

LV-2G UNic^® represents next generation vector technology, engineered to elevate lentiviral titers across a wide array of expression systems. The technology drives enhanced infectious viral particle production, by providing a significant boost in gRNA production through increased transcription levels achieved with ProteoNic's patented Dual Promoter system.

Participation in the LV-2G UNic^® Early Access Program offers exclusive benefits, including access to ProteoNic's cutting-edge LV-2G UNic^® vector technology, optimizing lentiviral particle expression and co-development opportunities. This technology can be seamlessly integrated into current workflows with minimal to no process development required.

For more information about LV-2G UNic^® and the Early Access Program, visit proteonic.nl

About ProteoNic BV

ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology and services for the generation of cell lines and viral vectors with greatly improved production characteristics. The company commercializes its proprietary 2G UNic^® technology through licensing and partnership arrangements.

For more information please contact:

ProteoNic BV

Jonathan Frampton, PhD
Director, Business Development
T: +44 7961 144115
E: frampton@proteonic.nl

 

Photo - https://mma.prnewswire.com/media/2373127/ProteoNic.jpg
Logo -  https://mma.prnewswire.com/media/1804728/ProteoNic_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/proteonic-unveils-early-access-program-elevating-viral-vector-titers-with-transformative-lv-2g-unic-technology-302100809.html